

REFERENCES

1. Danovitch GM. Handbook of kidney transplantation. 3rd ed. Philadelphia (PA): Lippincott Williams&Wilkins; 2001. p. 1-38.
2. Morris PJ. Kidney transplantation principles and practice. 5th ed. Philadelphia (PA): W.B. Saunders Company; 2001. p. 32-44 , 227-262.
3. Garovoy MR, Guttman RD. Renal transplantation. New York: Churchill Livingstone; 1986. p. 125-156.
4. <http://kidney.niddk.nih.gov/kudiseases/pubs/yourkidneys/#1> (25-6-2003)
5. Williot P. Chronic renal transplant rejection [online]. Available from: URL: <http://www.umanitoba.ca/faculties/medicine/units/surgery/scalpe/fall1998/chronicrenal.htm> (25-6-2003)
6. Min DI. Cyclosporine. In: Schumacher GE, editor. Therapeutic drug monitoring. Connecticut: Appleton & Lange; 1995. p. 449-463.
7. http://www.aacc.org/cln/series2002/drug_monitoring.pdf (23-6-2003)
8. Hallgren R, Engstrom-Laurent A, Nisbeth U. Circulating hyaluronate. A potential marker of altered metabolism of the connective tissue in uremia. Nephron 1987; 46(2): 150-154.

9. Hinghofer-Szalkay HG, Mekonen W, Rossler A, Schwabegger G, Lamprecht M, Hofmann P. Post-exercise decrease of plasma hyaluronan: increased clearance or diminished production ? *Physiol Res* 2002; 51: 139-144.
10. Surangkul D. The development of methods for quantitation of serum total sialic acid and hyaluronan [dissertation]. Chiang Mai: Chiang Mai Univ.; 1998.
11. Hallgren R, Gerdin B, Tufveson G. Hyaluronic acid accumulation and redistribution in rejecting rat kidney graft. Relationship to the transplantation edema. *J Exp Med* 1990; 171(6): 2063-2076.
12. Wells A, Larsson E, Hanas E, Laurent T, Hallgren R, Tufveson G. Increased hyaluronan in acutely rejecting human kidney grafts. *Transplantation* 1993; 55(6): 1346-1349.
13. Wells AF, Larsson E, Tengblad A, Fellstrom B, Tufveson G, Klareskog L, et al. The localization of hyaluronan in normal and rejected human kidneys. *Transplantation* 1990; 50(2): 240-243.
14. Stenvinkel P, Heimbürger O, Wang T, Lindholm B, Bergström J, Elinder CG. High serum hyaluronan indicates poor survival in renal replacement therapy. *Am J Kidney Dis* 1999; 34(6): 1083-1088.
15. Johnsson C, Hallgren R, Elvin A, Gerdin B, Tufveson G. Hyaluronidase ameliorates rejection-induced edema. *Transpl Int* 1999; 12(4): 235-243.
16. Knoflach A, Azuma H, Magee C, Denton M, Murphy B, Lyengar A, et al. Immunomodulatory functions of low-molecular weight hyaluronate in an acute rat renal allograft rejection model. *J Am Soc Nephrol* 1999; 10(5): 1059-1066.

17. Knoflach A, Magee C, Denton MD, Kim KS, Buelow R, Hancock WW, et al. Immunomodulatory functions of hyaluronate in the LEW-to-F344 model of chronic cardiac allograft rejection. *Transplantation* 1999; 67(6): 909-914.
18. Zhang W, Gao L, Qi S, Liu D, Xu D, Peng J, et al. Blocking of CD44-hyaluronic acid interaction prolongs rat allograft survival. *Transplantation* 2000; 69(4): 665-667.
19. Hellkvist J, Tufveson G, Gerdin B, Johnsson C. Characterization of fibroblasts from rejecting tissue: the hyaluronan production is increased. *Transplantation* 2002; 74(12): 1672-1677.
20. <http://www.home.eznet.net/~webtent/cyclosporine.html> (23-6-2003)
21. <http://www.ermm.cbcu.cam.ac.uk/00001782h.htm> (23-6-2003)
22. Facts and Comparisons. *Drugs facts and comparisons* 2002. Missouri: A Wolters Kluwer Company; 2001. p. 1692-1694.
23. <http://www.rxlist.com/cgi/generic2/tacrolimuspo.htm> (25-6-2003)
24. <http://www.home.eznet.net/~webtent/tacrolimus.html> (23-6-2003)
25. Knudson W, Knudson CB. The hyaluronan receptor, CD44 [online]. Available from: URL: <http://www.glycoforum.gr.jp/science/hyaluronan/HA10/HA10E.html> (25-6-2003)
26. Laurent TC, Laurent UB, Fraser JRE. Serum hyaluronan as a disease marker. *Ann Med* 1996; 28(3): 241-253.
27. Laurent TC, Fraser JRE, Pertoft H, Smedsrod B. Binding of hyaluronate and chondroitin sulfate to liver endothelial cells. *Biochem J* 1986; 234: 653-658.

28. <http://www.glycoforum.gr.jp/science/hyaluronan/HA01/HA01E.html> (25-6-2003)
29. Abbott Laboratory. TDx system. Operator's guide. Irving (TX); 1985.
30. <http://www.abbottlabs.com.au/html/add/medcond/meia.html> (26-6-2003)
31. Yingsang W. The development of a simple method for hyaluronan determination using biotinylate technique [dissertation]. Chiang Mai: Chiang Mai Univ.; 1996.
32. Goldberg RL, Huff JP, Lenz ML, Glickman P, Katz R, Thonar EJMA. Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. *Arthritis Rheum* 1991; 34 (7): 799-807.
33. Souillou JP. Immune monitoring for rejection of kidney transplants. *N Engl J Med* 2001; 344 (13): 1006-1007.
34. Hesselink DA, Van-Schaik RHN, Van der Heiden IP, Van der Werf M, Smak Gregoor PJH, Lindemans J et al. Genetic polymorphisms of the *CYP3A4*, *CYP3A5*, and *MDR-1* genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. *Clinical Pharmacology & Therapeutics* 2003; 74 (3): 245-254.
35. Pure E, Cuff CA. A crucial role for CD44 in inflammation. *Trends in molecular medicine* 2001; 7 (5): 213-221.
36. Heldin P, Laurent TC, Heldin CH. Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. *Biochem J* 1989; 258(3): 919-22.